Pervin Işeri1, Ilknur Başyiğit2, Ciğdem Ozerdem1, Hüseyin Başyiğit3, Hüsnü Efendi1, Füsun Yıldız2. 1. Department of Neurology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. 2. Department of Chest Diseases, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey. 3. Hospital Pharmacy, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
Abstract
OBJECTIVE: The aim of this study was to evaluate whether there was a relationship between severity of multiple sclerosis (MS) exacerbation and pulmonary function test (PFT) and to determine the effect of theophylline, which was added to intravenous methylprednisolone, on serum Tumor Necrosis Factor (TNF)-alpha levels and clinical scores in MS relapses. STUDY DESIGN: Double blind randomized controlled trial. MATERIAL AND METHODS: The baseline Expanded Disability Status Scale (EDSS) score was determined, PFT was performed and blood was taken for analysis of TNF- alpha in patients with MS exacerbation. Patients were randomly divided into two groups; group 1 received intravenous methylprednisolone+IV theophylline and group 2 intravenous methylprednisolone+placebo for 5 days. PFT and EDSS score were repeated and blood was taken for TNF-alpha on the 5(th) and 30(th) days of the treatment. RESULTS:Twenty-four patients (14 female, 10 male) were included in the study. Mean age was 32.6±9, duration of disease was 5.4±4.2 years, number of exacerbations was 5±2. There was a significant correlation between the number of exacerbations and EDSS score (p=0.000, r=1). Restrictive PFT findings were detected in 8 and decrease in carbon monoxide diffusing capacity (DLCO) in 3 cases. In within-group analysis, EDSS score was found to be decreased on day 5 and still low on day 30 in the theophylline group (baseline 3±1.3; 5(th) day 2.4±1.6; 30(th) day 2±1.7). There was no statistically significant difference in the EDSS score of the placebo group (3±1.6; 2.8±1.7; 2.4±1.9 respectively). While serum TNF-alpha level was not changed in the placebo group, there was a non-significant decrease on day 5 and increase on day 30 in the theophylline group. There was no correlation between the clinical parameters, PFT and TNF-alpha level. CONCLUSION: There was no correlation between severity of MS and PFT findings. It is suggested that theophylline might be effective in MS exacerbations since it caused decreases in clinical scores; studies with longer treatment duration are needed to clarify its possible anti-inflammatory effect.
RCT Entities:
OBJECTIVE: The aim of this study was to evaluate whether there was a relationship between severity of multiple sclerosis (MS) exacerbation and pulmonary function test (PFT) and to determine the effect of theophylline, which was added to intravenous methylprednisolone, on serum Tumor Necrosis Factor (TNF)-alpha levels and clinical scores in MS relapses. STUDY DESIGN: Double blind randomized controlled trial. MATERIAL AND METHODS: The baseline Expanded Disability Status Scale (EDSS) score was determined, PFT was performed and blood was taken for analysis of TNF- alpha in patients with MS exacerbation. Patients were randomly divided into two groups; group 1 received intravenous methylprednisolone+IV theophylline and group 2 intravenous methylprednisolone+placebo for 5 days. PFT and EDSS score were repeated and blood was taken for TNF-alpha on the 5(th) and 30(th) days of the treatment. RESULTS: Twenty-four patients (14 female, 10 male) were included in the study. Mean age was 32.6±9, duration of disease was 5.4±4.2 years, number of exacerbations was 5±2. There was a significant correlation between the number of exacerbations and EDSS score (p=0.000, r=1). Restrictive PFT findings were detected in 8 and decrease in carbon monoxide diffusing capacity (DLCO) in 3 cases. In within-group analysis, EDSS score was found to be decreased on day 5 and still low on day 30 in the theophylline group (baseline 3±1.3; 5(th) day 2.4±1.6; 30(th) day 2±1.7). There was no statistically significant difference in the EDSS score of the placebo group (3±1.6; 2.8±1.7; 2.4±1.9 respectively). While serum TNF-alpha level was not changed in the placebo group, there was a non-significant decrease on day 5 and increase on day 30 in the theophylline group. There was no correlation between the clinical parameters, PFT and TNF-alpha level. CONCLUSION: There was no correlation between severity of MS and PFT findings. It is suggested that theophylline might be effective in MS exacerbations since it caused decreases in clinical scores; studies with longer treatment duration are needed to clarify its possible anti-inflammatory effect.
Authors: T Yoshimura; T Nagao; T Nakao; S Watanabe; E Usami; J Kobayashi; F Yamazaki; H Tanaka; N Inagaki; H Nagai Journal: Gen Pharmacol Date: 1998-02
Authors: F Nicoletti; R Di Marco; F Patti; P Zaccone; M R L'Episcopo; E Reggio; M Xiang; A Nicoletti; A Reggio Journal: Cytokine Date: 2000-06 Impact factor: 3.861
Authors: V Navikas; D Matusevicius; M Söderström; R Pirskanen; S Fredrikson; H Link Journal: Clin Neuropharmacol Date: 1998 Jul-Aug Impact factor: 1.592
Authors: P Rieckmann; M Albrecht; B Kitze; T Weber; H Tumani; A Broocks; W Lüer; A Helwig; S Poser Journal: Ann Neurol Date: 1995-01 Impact factor: 10.422
Authors: P Rieckmann; F Weber; A Günther; S Martin; A Bitsch; A Broocks; B Kitze; T Weber; T Börner; S Poser Journal: J Neuroimmunol Date: 1996-02 Impact factor: 3.478